Will list German arm Syngene in next 12 months: Biocon

Channel:
NDTV Profit Markets
Subscribers:
134,000
Published on ● Video Link: https://www.youtube.com/watch?v=n3URuNVITUk


Duration: 7:37
183 views
1

Kiran Mazumdar Shaw, Chairman of Biocon speaks about the Espirto Santo report that questions the company's accounting standards, Axi Corp, insulin business, Pfizer deal, Statin business, listing of German arm Syngene. She says that margins have improved after Axi Corp exit.



Other Videos By NDTV Profit Markets


2012-05-26Plan to award contract to develop 9000 km in FY13: NHAI
2012-05-26Expect execution of 14,000-15,000 MW of power: BHEL
2012-05-26REC to raise $1bn via FCCBs; $750 mn ECB in FY13
2012-05-24Hope govt hikes Diesel, LPG prices: BPCL
2012-05-24Is such a steep petrol price hike justified?
2012-05-24FIIs selling on fears of further drop in rupee: experts
2012-05-24Is white paper on black money a damp squib?
2012-05-23Challenges to rupee feeding on themselves: Chanda Kochhar
2012-05-23Weak rupee a silver lining for IT: Vineet Nayyar
2012-05-23See rupee in near 60/$: Jamal Mecklai
2012-05-23Will list German arm Syngene in next 12 months: Biocon
2012-05-22Rupee most vulnerable of Asian currencies: Nomura
2012-05-22If I were in UPA-II, I would not celebrate: Kiran Mazumdar Shaw
2012-05-22We Mean Business: Are changes to the land bill anti-industry?
2012-05-22Has UPA-II killed the India story?
2012-05-21Pension scheme let down by poor marketing, distribution: PFRDA chairman
2012-05-21Flipping through Soli Sorabjee's diverse books
2012-05-21Q4 profit driven by commercial finance, broking: Reliance Capital
2012-05-21Volatile vegetable prices causing inflation: VS Vyas
2012-05-21Ertiga sees over 40,000 bookings; sales not good in April, May: Maruti
2012-05-21Q1 NIM likely to be around 3.75%: SBI chairman


Tags:
Corporates
Kiran
Mazumdar
Shaw
Biocon
Espirto
NDTV
Profit